Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sym004
Sym004
Merck KGaA abandons Symphogen's cancer drug ahead of Phase III
Fierce Biotech
Thu, 01/29/15 - 09:39 am
Merck KGaA
Symphogen
Sym004